Recombinant CD22 (Epratuzumab Biosimilar) antibody
Reactivity: Cynomolgus, Human, Rhesus Monkey
BP, FACS, IP
Host: Human
Monoclonal
hL22
unconjugated
Recombinant Antibody
-
- Target See all CD22 (Epratuzumab Biosimilar) products
- CD22 (Epratuzumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Cynomolgus, Human, Rhesus Monkey
-
Host
-
Human
-
Clonality
- Monoclonal
-
Conjugate
- This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated
- Application
- Blocking Peptide (BP), Flow Cytometry (FACS), Immunoprecipitation (IP)
- Specificity
- This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
- Characteristics
-
OriginalSpeciesName: Human
OriginalFormat: IgG1
- Purification
- Purified antibody.
- Purity
- > 98 % as determined by SDS-PAGE
- Endotoxin Level
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
- Immunogen
- This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
- Clone
- HL22
- Isotype
- IgG1 kappa
-
anti-CD22 (Epratuzumab Biosimilar) antibody
Reactivity: Cynomolgus, Human, Rhesus Monkey BP, FACS, IP Host: Rabbit Monoclonal hL22 unconjugated Recombinant Antibody
-
- Application Notes
- Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).
- Restrictions
- For Research Use only
-
- Buffer
- PBS with 0.02 % Proclin 300.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Target
- CD22 (Epratuzumab Biosimilar)
- Abstract
- CD22 (Epratuzumab Biosimilar) Products
- Synonyms
- SIGLEC-2 antibody, SIGLEC2 antibody, CD22 molecule antibody, CD22 antibody
- Target Type
- Biosimilar
- Background
- Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
- UniProt
- P20273
-
You are here:
